IRONWOOD PHARMACEUTICALS, INC. Defined Benefit Plan, Accumulated Benefit Obligation
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Defined Benefit Plan, Accumulated Benefit Obligation of $15.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan
us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation · last filed 2026-02-26
- 2025-12-31: Defined Benefit Plan, Accumulated Benefit Obligation $15.00M.
- 2024-12-31: Defined Benefit Plan, Accumulated Benefit Obligation $17.90M.
| Period end | Defined Benefit Plan, Accumulated Benefit Obligation |
|---|---|
| 2025-12-31 | $15.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $17.90M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |